Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.840 +0.230 (+4.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
 
Via Benzinga
Recap: Arbutus Biopharma Q1 Earnings
 
Via Benzinga
Arbutus Biopharma's Earnings Outlook
 
Via Benzinga
Why Arbutus Biopharma Stock Is Sinking Today
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump. 
Via The Motley Fool
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Why Arbutus Biopharma Stock Is Plunging Today
 
Via Benzinga
Arbutus to Present at Jefferies Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Present at JMP Securities Life Sciences Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
 
Via Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
 
Via Benzinga
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus to Participate in Three Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces Resignation of Board Member
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.